Menu
Expand your knowledge.
Endocrinologist Dr. Kenneth Cusi and hepatologist Dr. Mazen Noureddin join forces to shine a light on the emerging fatty liver disease epidemic, and what it will take to overcome this health burden.
Key points to be covered:
Dr. Cusi is a Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism at The University of Florida at Gainesville, and at the Veterans Administration Medical Center at Gainesville, FL (2011-Present).
He completed his medical training and residency in Buenos Aires, Argentina, and fellowship in endocrinology at Baylor College of Medicine, Houston, Texas. He worked after his training at the University of San Antonio Health Science Center, Texas (1992-2011) on the role of defects in insulin secretion/insulin resistance in the development of T2DM and later focused on the underlying mechanisms and new treatments for nonalcoholic fatty liver disease (NAFLD) in T2DM.
Dr. Cusi has published over 200 original articles, editorials, reviews and book chapters in the fields of diabetes, obesity and liver disease.
Dr. Noureddin is the founding director of the Fatty Liver Program at Cedars-Sinai Medical Center. His focus is on clinical and translational research in the area of NAFLD/NASH and NASH related cirrhosis.
Dr. Noureddin has conducted more than 40 investigational clinical studies of novel treatments for NASH. In addition, he has an interest in non-invasive testing and biomarkers of the field, especially metabolomics, serum biomarkers, transient elastography, and magnetic resonance imaging techniques. He has published in all these areas.
He has given invited lectures on NAFLD/NASH at national and international society meetings and serves on several steering committees/advisory boards for industry. He is the chair of the AASLD NASH special interest group education sub-committee and serves on the editorial board for the journals “Clinical Gastroenterology and Hepatology (CGH)” and “Gastroenterology”.
Henry E. Chang is the Executive Director of the Fatty Liver Foundation (FLF) and a co-founder and CEO of Health Business Solutions. Prior to joining FLF, Henry was involved in the creation and implementation of many of the world’s most respected philanthropic and humanitarian initiatives in global health.
Henry has extensive experience of working in various patient advocacy organizations, basic and clinical research agencies, and life science industry in executive leadership and senior advisory positions, including the Global Business Coalition on HIV/AIDS, Tuberculosis, and Malaria, Doctor of the World/Médecins du Monde USA, AIDS Healthcare Foundation, AIDS Coalition to Unleashed Power (ACT-UP/Los Angeles), the U.S. National Institute of Allergy and Infectious Diseases (NIAID), DuPont Merck Pharmaceutical Company, and DuPont Pharmaceuticals.
